Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution

Supraclavicular Block Clinical Trial

Official title:

Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01583179
• Other study ID #: 2011-0781
• Secondary ID: SMPH/ANESTHESIOA
• Status: Terminated
• Phase: N/A
• Start date: April 2012
• Est. completion date: December 2015

Study information

• Verified date: September 2019
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The patients included will be those who have already agreed to have a brachial plexus nerve block for surgery. A flip of the coin will decide who gets and additive called buprenorphine in their block or not. They will both contain the same amount and type of numbing medicine. The goal will be to see if the additive extends the life of the pain control portion of the ultrasound guided supraclavicular nerve block.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: December 2015
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

1. American Society of Anesthesiologists (ASA) physical status 1-3

2. Age 18-79, inclusive

3. BMI <36 kg/m^2

4. Patient consenting to single injection brachial plexus nerve block as primary anesthetic for a procedure

Exclusion Criteria:

1. Patients with coagulation disorders

2. Clinically significant pulmonary disease

3. Clinically significant cardiac disease

4. Neurologic deficit in surgical extremity

5. Allergy to bupivacaine or buprenorphine

6. Intolerance of narcotics

7. Local infection over intended area of needle insertion

8. Hepatic failure or renal failure

9. Significant psychiatric disease, including drug abuse

10. Seizure disorder

11. Possible pregnancy or lactation by patient report

12. Use of narcotic medication greater than 2 times a week for greater than 1 week.

13. Patients for whom the surgeon requests a shorter-acting block

Related Conditions & MeSH terms

• Block Additive
• Regional Block for Pain Control
• Supraclavicular Block
• Ultrasound Guided Block

Intervention

Drug:
• Buprenorphine
added to nerve block, 0.3mg one time peripheral block use

Locations

Country	Name	City	State
United States	University of Wisconsin	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time Until First Pain Medication Post-operatively	Time in minutes until first pain medication was take by participant post-operatively	48 hrs
Secondary	Pain Score on Post Operative Day 1	pain score on post operative day 1 was measured on a scale 1-10. higher scores correlates with more severe pain. score range is from '0' (no pain) to 10 (pain as severe as it can be)	1 day postoperative